Ophthalmology
-
Comparative Study
Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration.
We sought to determine the most cost-effective treatment for patients with newly diagnosed neovascular macular degeneration: monthly or as-needed bevacizumab injections, or monthly or as-needed ranibizumab injections. ⋯ Even after considering the potential for differences in risks of serious adverse events and therapeutic effectiveness, bevacizumab confers considerably greater value than ranibizumab for the treatment of neovascular macular degeneration.